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Abstract The role of platelet receptor gain-of-function
single nucleotide polymorphisms (SNP) in cardiovascular
disease is controversial. We hypothesised that certain SNPs
may accelerate the development of carotid artery stenosis.
The intronic PAR-1 receptor intervening sequence-14 A/T
(IVSn-14 A/T) polymorphism and three additional platelet
receptor polymorphisms, i.e. GPIa (807C/T), GPIba (5T/C)
and HPA-1a/HPA-1b (Pl (A1/A2)) of GPIIIa were studied.
The interaction of SNPs with conventional risk factors
including male gender, hypertension, high cholesterol, dia-
betes, advanced age and smoking were investigated. The
hypothesis was tested in 114 well-characterised patients with
symptomatic carotid or vertebral stenosis from the British
CAVATAS population and compared the results with 97
unrelated controls. The allele frequency of the platelet gain-
of-function SNP was not significantly different in the CAV-
ATAS population as compared to controls (PAR-1A/T
(P = 0.13), GPIa C/T (P = 0.25), GPIIIa HPA-1a/HPA-1b
(PlA1/A2) (P = 0.66) and GPIb T/C (P = 0.20)). In the
subgroup of smokers, however, the prothrombotic GPIba C
mutated allele was found in a significantly higher frequency
in the patient as compared to the control group (P = 0.04).
Contrary to the primary hypothesis, the PAR-1A/T SNP as
well as the other SNPs tested were not over- or underrepre-
sented in the CAVATAS population. However, a significantly
increased prevalence of GPIb-a (5C/T) was found in the
subgroup of smokers and may represent an important cofactor
in this patient group of our hypothesis-generating study.
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Introduction
Platelet receptor polymorphisms that result in a ‘‘gain-
of-function’’ in platelet adhesion and/or aggregation due to
increased receptor density or affinity and increased platelet
activation may place carriers at increased risk of vascular
events and accelerate atherogenesis. Indeed, platelet
adhesion to dysfunctional endothelium and activation with
subsequent degranulation are important elements of the
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formation and kinetics of atherosclerotic lesions [1], which
may be accelerated by gain-of-function platelet polymor-
phisms. Several such mutations have been described, but
their contribution to clinical events remains controversial
[2–7].
On this basis, we hypothesised that platelet gain-
of-function polymorphisms may predispose carriers to an
accelerated development of atherosclerosis, especially in
combination with exogenous risk factors.
Thrombin is known to increase vascular smooth muscle
cell (VSMC) proliferation and migration (i.e. crucial
mechanisms of atherosclerosis and neointima formation),
and PAR-1 is widely expressed in VSMC in human ath-
eromas indicating a role of this receptor in atherogenesis
[8–11]. Therefore, our primary hypothesis was that the
intronic PAR-1 receptor intervening sequence-14 A/T
(IVSn-14 A/T) polymorphism would enhance local
thrombin growth factor effects and accelerate the devel-
opment of atherosclerotic lesions. So far, the association of
this mutation with clinical events has not been investigated
[12].
Three additional gain-of-function platelet-receptor sin-
gle nucleotide polymorphisms (SNPs) of GPIba (5T/C),
GPIa (807C/T) and GPIIIa (HPA-1a/HPA-1b (also called
PlA1/A2)) served as secondary endpoints, which have been
demonstrated to increase clinical events, likely due to their
gain-of-function mechanisms [4, 12–15] in addition to their
interaction with behavioural risk factors. The GPIba (5T/C)
SNP was of particular interest, since the A1 binding site of
von Willebrand factor (vWF) may be activated to bind
platelet GPIba under high shear stress, as it occurs in ste-
notic atherosclerotic lesions [16–19]. So far, clinical stud-
ies investigating the implications of the GPIba (5T/C)
polymorphism have yielded controversial results [4–7, 20].
Of particular interest was the combination of these poly-
morphisms with smoking (an acquired risk factor) as ear-
lier studies have reported a strong association of smoking
and platelet SNP with clinical events [21, 22].
Materials and methods
Study population
In the carotid and vertebral artery transluminal angioplasty
study (CAVATAS), 504 patients with high grade carotid
stenosis were randomised for endovascular versus surgical
treatment [23]. Patients from this international multicentre
study provide a well-characterised model population with a
clearly defined carotid stenosis, in which gain-of-function
polymorphisms could be correlated to the human situation
of advanced atherosclerosis. After obtaining written
informed consent, blood samples were taken from 114
CAVATAS patients from the British cohort in London and
Sheffield [23]. The CAVATAS trial enrolled patients with
carotid stenosis suitable for both carotid endarterectomy
and endovascular treatment. Exclusion criteria included
patients thought to be unsuitable for surgery because of
medical or surgical risk factors (e.g., recent myocardial
infarction, poorly controlled hypertension or diabetes
mellitus, renal disease, respiratory failure, inaccessible
carotid stenosis, or severe cervical spondylosis). Patients
were also excluded if they were unable to give informed
consent, or if they had a disabling stroke with no useful
recovery of function within the region supplied by the
treatable artery. There was no age limit. The available
partners of the patients served as unrelated controls (97
samples). All controls had a negative history for myocar-
dial infarction, angina, claudication, heart failure, stroke/
transient ischemic attack. The study was approved by the
local internal review board (IRB).
While designing this hypothesis generating study we
were careful to follow the standards of genetic association
studies in stroke proposed by Dichgans and Markus [24].
To assess and compare the allelic frequency of platelet
receptor SNP in an additional large representative control
sample of a healthy Caucasian population, blood from 979
healthy Swiss blood donors was analysed.
Detection of polymorphisms
The polymorphisms were determined by the kinetic ther-
mocycling method (KTC) [25, 26]. The single nucleotide
polymorphisms (SNP) for GPIa C807T and GPIIIa HPA-
1a/HPA-1b were determined by the polymerase chain
reaction and melting point analysis with fluorescent
hybridisation probes by using the fluorescence energy
transfer principle (LightCycler System, Roche, Basel,
Switzerland).
Statistical analysis
We hypothesised that CAVATAS patients with carotid
stenosis have a higher frequency of the prothrombotic AA
(or lower TT)-SNP of PAR-1 (primary endpoint). As sec-
ondary endpoints, the association of the other three SNPs
with carotid stenosis and their interaction with smoking
were evaluated in an exploratory manner.
In our previous study [21] a relative risk of about 3.3 for
patients with myocardial infarction who carry the collagen
GPIa/IIa polymorphism (prevalence in the general popu-
lation 5%) has been found. Coronary restenoses appear to
occur in the presence of the GP IIb/IIIa polymorphism
(prevalence 20%) at an odds ratio of 1.5–3 [27]. As for the
Kozak polymorphism (GP1b) (allele frequency 8–17% in
the general population) a conservative estimate may be in
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the range of a RR of 2–3. On the basis of these previous
studies, expected restenosis rates [21, 27] and allele fre-
quencies in a total of 200 (GP IIIa and GPIa) or 250 (GPIb)
patients respectively will achieve a power of 80% (a two-
sided 0.05).
Differences in SNP frequencies were assessed using
Fisher’s exact test. Additionally, a multiple logistic
regression model with forward selection was fitted with the
four SNPs and was adjusted for other confounding risk
factors including male gender, hypertension, high choles-
terol, diabetes, advanced age and smoking (only subjects
with complete data for gender, hypertension, cholesterol,
diabetes, age and smoking were included in this analysis).
A significance level of 0.1 was used for the forward
selection. For all other tests, a significance level of 0.05
was used. Statistical analyses were conducted using SAS
System 9.1 (SAS Institute, Cary, NC, USA). The study was
planned and conducted according the previously proposed
standard criteria [24].
Results
Baseline characteristics and distribution of cardiovascular
risk factors are summarised in Table 1. As expected, the
prevalence of the cardiovascular risk factors: male gender
(P = 0.006), hypertension (P \ 0.0001), high cholesterol
(P = 0.004), advanced age (P \ 0.0001) and smoking
(P = 0.014) were higher in the patient group as compared
to controls.
The results of the distribution of the individual point
mutations are summarised in Table 2. The allele frequen-
cies of the PAR-1 SNP were similar among the patient and
control groups (Fisher’s exact test, P = 0.13). Likewise, no
significant difference was observed between the two groups
with respect to GPIa (P = 0.25), GPIIIa (P = 0.66) and
the GPIba SNP (Fisher’s exact test, P = 0.20).
The multiple logistic regression model with forward
selection included the factors hypertension (P \ 0.0001),
age (P \ 0.0001), sex (P = 0.006), cholesterol (P =
0.004) and smoking (P = 0.014). The odds ratio estimators
were 4.89 (95% CI 2.17–11.58) for hypertension, 1.14
(1.08–1.20) for age, 4.54 (2.06–10.64) for male gender,
4.24 (1.87–10.22) for cholesterol, 2.58 (0.96–7.34) for
smokers versus non-smokers, and 0.35 (0.10–1.13) for
ex-smokers versus non-smokers. For example, an individ-
ual with hypertension has 4.89 times higher odds of being
in the patient group than an individual without; likewise, or
an individual who is 1 year older has 1.14 times higher
odds to be in the patient group.
When patients were separated according to smoking
status (i.e. non-smokers, ex-smokers and current smokers),
the GPIba mutation was overrepresented in the subgroup of
current smokers (P = 0.044, Table 3). In this group, the
GPIba mutation was included in the multiple logistic
regression model with forward selection. The odds ratio
estimators were 11.83 (95% CI 1.30–231.65) for the GPIba
mutation, 4.59 (0.90–28.47) for dyslipidaemia, and 1.17
(1.05–1.35) for advanced age. Hence, an individual with
the prothrombotic GPIba (5C) allele is at 11.8 times higher
odds to be in the patient group than an individual without
this allele (in the subgroup of smokers). Analyses testing
interaction between SNPs and the smoking status (includ-
ing current smokers, ex-smokers and non-smokers) did not
reveal any statistically significant result (Tables 4, 5).
According to previous published guidelines [24], we
also tested if the marker genotypes were in Hardy–
Weinberg equilibrium in CAVATAS patients and controls.
In the CAVATAS group only PAR-1 Sn-14A/T was sig-
nificant (P = 0.04), and in the control group only platelet
GPlba were significant (P = 0.04). Upon adjustment of the
P-values for multiple statistical testing by Bonferroni cor-
rection, no P-value remains significant. Therefore, we may
state that the marker genotypes are within a Hardy–
Weinberg equilibrium [24, 28].
Table 1 Baseline characteristics and distribution of cardiovascular
risk factors in CAVATAS patients and controls
Patients (n = 114) Controls (n = 97) P-values
Gender
Male 73 (64.0%) 40 (41.2%) 0.006
Female 33 (29.0%) 56 (57.7%)
n/a 8 (7.0%) 1 (1.0%)
Age
Mean 71.5 63.3 \0.0001
n/a 8 1
Smoking
Current 25 (21.9%) 17 (17.5%) 0.014
Never 73 (64.0%) 53 (54.6%)
Ex-smoker 8 (7.0%) 20 (20.6%)
n/a 8 (7.0%) 7 (7.2%)
Hypertension
Yes 81 (71.1%) 39 (40.2%) \0.0001
No 21 (18.4%) 52 (53.6%)
n/a 12 (10.5%) 6 (6.2%)
Diabetes
Yes 11 (9.7%) 12 (12.4%) n/s
No 89 (78.1%) 79 (81.4%)
n/a 14 (12.3%) 6 (6.2%)
High cholesterol
Yes 68 (59.7%) 38 (39.2%) 0.004
No 28 (24.6%) 49 (50.5%)
n/a 18 (15.8%) 10 (10.3%)
n/a Not available, n/s not significant
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The overall frequency of the platelet receptor point
mutations in the CAVATAS population and the respective
controls was similar to a large representative control cohort
of healthy Swiss blood donors (data not shown) suggesting
that ethnicity did not play a role in these analyses.
Discussion
Contrary to our primary hypothesis, the PAR-1 (IVSn-14)
SNP was not associated with symptomatic carotid stenosis.
Furthermore, the three other ‘‘prothrombotic’’ platelet
receptor SNPs were not overexpressed in patients. How-
ever, a significantly increased prevalence of GPIb-a (5C/T)
was found in the subgroup of smokers, a typical exogenous
atherogenic risk factor.
The study of gain-of-function polymorphisms is justified
as they potentially increase the carrier’s risk of athero-
sclerosis and/or vascular events. Indeed, platelet adhesion
to dysfunctional endothelium and activation with sub-
sequent degranulation are important elements of athero-
sclerotic lesion formation [1]. Polymorphism in the Kozak
sequence of GpIba is a major determinant of mRNA
translation and, thus, the amount of GPIb present on the
platelet surface, which is increased by the presence of the C
allele at the -5 position [4, 29]. This receptor and its
interaction with vWF is of particular interest, because it is
functional at the high shear rates found in arterial stenosis.
Its inhibition results in reduced generation of platelet
derived microparticles, thrombin generation and procoag-
ulant activity at high shear forces [17, 18]. Furthermore, in
vitro studies have shown that platelet membrane glyco-
protein polymorphisms (including the Kozak sequence)
influence experimental thrombus formation at typical shear
rates [30]. So far, clinical studies investigating the impli-
cations of the GPIba (5T/C) polymorphism have yielded
controversial results. In 219 cases of first-ever ischemic
stroke, presence of the C allele (as evidenced by an
increased frequency of the T/C genotype) was overrepre-
sented in the stroke group as compared to healthy controls
even after adjusting for conventional risk factors [4]. In a
study of 1000 patients with angiographically confirmed
coronary artery disease, the GPIba (5C) allele represented a
Table 2 Summary of the distribution of the four polymorphisms in
the CAVATAS patient cohort and controls
CAVATAS patients Controls P-value
PAR-1 Sn-14A/T
AA 83 (72.8%) 68 (70.1%)
AT 25 (21.9%) 28 (28.9%)
TT 6 (5.3%) 1 (1.0%)
Total number 114 97 0.13
Odds ratio: 0.19 95% CI 0.02–1.59
Platelet GpIb-a (5T/C)
CC 0 (0.0%) 0 (0.0%)
CT 23 (20.2%) 27 (27.8%)
TT 91 (79.8%) 70 (72.2%)
Total number 114 97 0.20
Odds ratio: 0.65 95% CI 0.35–1.24
Platelet GpIa 807 C/T
CC 43 (37.7%) 43 (44.3%)
CT 57 (50.0%) 36 (37.1%)
TT 14 (12.3%) 18 (18.6%)
Total number 114 97 0.25
Odds ratio: 1.63 95% CI 0.76–3.47
Platelet GpIIIa (HPA-1a/HPA-1b; PI A1/A2)
PI A2/A2 4 (3.5%) 3 (3.1%)
PI A1/A2 36 (31.6%) 28 (28.9%)
PI A1/A1 74 (64.9%) 66 (68.0%)
Total number 114 97 0.66
Odds ratio: 1.15 95% CI 0.65–2.04
The data collectively show no difference between the patients with
carotid stenosis and the British controls. The underlined allele rep-
resents ‘‘the risk allel’’
The calculated P-values are for risk allele versus no risk allele (e.g. in
A): A is the risk allele therefore, AA and AT are tested versus TT
Table 3 Distribution of the four polymorphisms in the subgroup of
smokers
CAVATAS patients Controls P-value
PAR-1 Sn-14A/T
AA 16 (66.7%) 10 (62.5%)
AT 7 (29.2%) 6 (37.5%)
TT 1 (4.2%) 0 (0%)
Total number 24 16 n/s
Platelet GpIb-a (5T/C)
CC 0 (0.0%) 0 (0.0%)
CT 6 (25.0%) 2 (12.5%)
TT 18 (75.0%) 14 (87.5%)
Total number 24 16 0.044
Platelet GpIa 807 C/T
CC 5 (20.8%) 6 (37.5%)
CT 16 (66.7%) 8 (50%)
TT 3 (12.5%) 2 (12.5%)
Total number 24 16 n/s
Platelet GpIIIa (HPA-1a/HPA-1b; PI A1/A2)
PI A2/A2 0 (0.0%) 1 (6.3%)
PI A1/A2 7 (29.2%) 6 (37.5%)
PI A1/A1 17 (70.8%) 9 (56.3%)
Total number 24 16 n/s
The data show an increased prevalence of the GpIba C allele in the
CAVATAS patients as compared to the controls. The underlined allel
represents ‘‘the risk allele’’
n/s Not significant
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risk factor for thrombotic events [5]. Similarly, in a mul-
ticentre case–control study, homozygous C/C genotype
carriers had a 3.5-fold increased risk for ischaemic cere-
brovascular events as compared to T/T or T/C genotype
carriers together (independent of atherosclerotic risk fac-
tors), indicating a role of this allele in arterial thrombosis
[6]. On the other hand, young women with the C allele of
the GPIba polymorphism do not appear to be at increased
risk of myocardial infarction or non-fatal stroke, even in
the subgroup of smokers [7]. The discrepancies between
these studies may be accounted for by different patient
selection criteria and studied outcomes, population size,
age and other factors. A recent meta-analysis indicated a
strong association of the -5T/C polymorphism with the
risk of ischaemic stroke. However, the direction of asso-
ciation was highly variable, suggesting that despite the
presence of an association signal the true causative locus is
perhaps not the Kozak -5T/C sequence itself but rather a
gene region nearby [20].
The interaction of the polymorphisms in smokers was of
particular interest, as we have previously demonstrated the
association of two silent and linked polymorphisms (807C/
T and 873G/A) within the GPIa gene with the risk of
myocardial infarction, which was strongest in the subgroup
of smokers [21]. In the same line, polymorphisms of the
GPIIb/IIIa gene and smoking were shown to affect the risk
of stroke (while the SNP in itself did not) [22]. Our
observation of an increased frequency of the GPIba-5C
allele in smokers with established atherosclerosis is in
agreement with and extends these previous findings, not
only for the ischemic events but also for the preceding
development of arterial stenoses. In our present study, the
odds estimator of the effect of the GPIba (5C) allele in this
subgroup was 11.83 while it was only 4.59 for hypercho-
lesterolemia, implying an even more important effect of the
GPIba mutation as compared to this well-established ath-
erogenic risk factor. However, given the small subgroup in
which this finding was detected (a = 0.05, b = 0.775) the
significant P-value should be used as hypothesis-generating
finding for further analysis in a larger population with a
matched pair control group.
An accelerated development of atherosclerotic lesions in
patients carrying the -5C allele may potentially occur
through an altered interaction of the GPIb–V–IX complex
with vWF and, subsequently, an enhanced interaction of
vWF with the (sub-) endothelium as proposed in Fig. 1. As
the A1 binding site of vWF may be activated to bind
platelet GPIba under high shear stress by anchoring of the
Table 4 Distribution of the four polymorphisms in the subgroup of
ex-smokers
CAVATAS patients Controls P-value
PAR-1 Sn-14A/T
AA 7 (87.5%) 13 (72.2%)
AT 1 (12.5%) 5 (27.8%)
TT 0 (0.0%) 0 (0.0%)
Total number 8 18 n/s
Platelet GpIb-a (5T/C)
CC 0 (0.0%) 0 (0.0%)
CT 1 (12.5%) 6 (33.3%)
TT 7 (87.5%) 12 (66.6%)
Total number 8 18 n/s
Platelet GpIa 807 C/T
CC 5 (62.5%) 10 (55.6%)
CT 3 (37.5%) 4 (22.2%)
TT 0 (0.0%) 4 (22.2%)
Total number 8 18 n/s
Platelet GpIIIa (HPA-1a/HPA-1b; PI A1/A2)
PI A2/A2 1 (12.5%) 1 (5.6%)
PI A1/A2 2 (25.0%) 5 (27.8%)
PI A1/A1 5 (62.5%) 12 (66.7%)
Total number 8 18 n/s
The underlined allel represents ‘‘the risk allele’’
n/s Not significant
Table 5 Distribution of the four polymorphisms in the subgroup of
non-smokers
CAVATAS patients Controls P-value
PAR-1 Sn-14A/T
AA 43 (71.7%) 36 (69.2%)
AT 12 (20.0%) 15 (28.9%)
TT 5 (8.3%) 1 (1.9%)
Total number 60 52 n/s
Platelet GpIb-a (5T/C)
CC 0 (0.0%) 0 (0.0%)
CT 11 (18.3%) 16 (30.7%)
TT 49 (81.7%) 36 (69.2%)
Total number 60 52 n/s
Platelet GpIa 807 C/T
CC 26 (43.3%) 24 (46.2%)
CT 25 (41.7%) 18 (34.6%)
TT 9 (15.0%) 10 (19.2%)
Total number 60 52 n/s
Platelet GpIIIa (HPA-1a/HPA-1b; PI A1/A2)
PI A2/A2 2 (3.3%) 1 (1.9%)
PI A1/A2 22 (36.7%) 14 (26.9%)
PI A1/A1 36 (60.0%) 37 (71.2%)
Total number 60 52 n/s
The underlined allel represents ‘‘the risk allele’’
n/s Not significant
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downstream A3 domain to collagen [16], mutation of the
GPIba gene may, furthermore, confer an increased
thrombotic risk especially in conditions with high shear
forces, as they occur in high-grade atherosclerotic lesions.
This could explain a potential risk for adverse events in
carriers of the GPIba (5C) mutation and in those who
smoke. Platelet binding to activated endothelium and/or
collagen at damaged sites will not only translate into
platelet plug formation but also to recruitment of mono-
cytes (e.g. by exposed p-selectins) and acceleration of
plaque formation and arterial stenosis [8], as may be the
case in the CAVATAS population of smokers.
Contrary to our initial hypothesis, mutations in the PAR-
1 (IVSn-14), GPIa (807 C/T) and GPIIIa (HPA-1a/HPA-
1b) gene were not overrepresented in patients with
symptomatic carotid artery stenosis as compared to con-
trols, which was also true for the subgroup analyses (data
not shown). Indeed, while earlier studies implied an asso-
ciation of SNP in the GPIa [31] or the GPIIIa [13, 32] gene
with clinical events, more recent data speak against this
hypothesis [33–35], which is in accord with our data. To
our knowledge, our study is the first to investigate an
association of the PAR-1 (IVSn-14) SNP with clinical
events [12, 15]. However, our data do not support a role of
this SNP in the development of atherosclerotic carotid
artery lesions.
In summary, our data show that none of the SNPs
studied are overrepresented in a general cohort of patients
with symptomatic carotid artery stenosis. Thus, their roles
as single atherogenic risk factors in the general population
remains to be determined. Although our findings are
‘‘negative’’ in this regard, they nevertheless appear to be
important, since publication bias towards ‘‘positive’’ find-
ings can severely skew the perception of polymorphisms
associated with clinical events as demonstrated in a recent
large-scale meta-analysis of polymorphisms in coronary
artery disease [36]. On the other hand, our analysis of
smokers revealed a significantly increased prevalence for
the GPIb-a (5C) allele in this subgroup (despite a relatively
low number of patients), which is in accord with and
extends earlier studies. Our data, nevertheless, point
towards a role of the GPIb-a (5C) allele as a synergistic
Fig. 1 Simplified overview of the interaction of GpIb–IX–V, von
Willebrand Factor (vWF), and collagen. The GpIb–IX–V complex
binds to the A1-binding site of vWF, while collagen, which may be
exposed following endothelial injury, is bound to the A3 binding site
of vWF. Gain-of-function mutation of the GpIb-a chain may influence
both the binding of GpIb–IX–V complex to vWF, as well as the
interaction of vWF with the (sub-) endothelium (e.g. via an increased
density and/or affinity of the collagen binding site of vWF)
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‘‘silent background risk factor’’, which is functional at high
shear stress and potentiated by a typical exogenous risk
resulting in accelerated atherosclerotic lesion formation. As
such, these findings may have important implications for
the carriers of this mutation, especially in the presence of
the additional exogenous and hence modifiable risk factor,
smoking.
One weakness of our study is that the calculated number
of patients was not achieved due to limitations of the time
frame for sample size collection. Nevertheless, even con-
sidering this small patient number, the study setting
detected an overrepresentation of GPIba in the subset of
smokers. Given the exploratory nature of this study, our
results should be viewed as hypothesis-generating. In view
of the wealth of accumulating data, however, the synergy
of arterial stenosis, high shear-favoured adhesion-
polymorphism of GPIba and smoking resulting in an
increased platelet/endothelial reactivity deserves further
exploration.
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